| IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade M Ayers, J Lunceford, M Nebozhyn, E Murphy, A Loboda, DR Kaufman, ... The Journal of clinical investigation 127 (8), 2930-2940, 2017 | 2879 | 2017 |
| Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ... Journal of Clinical Oncology 38 (1), 1, 2020 | 2199 | 2020 |
| Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort … A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, ... The Lancet Oncology 21 (10), 1353-1365, 2020 | 1637 | 2020 |
| Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study HC Chung, W Ros, JP Delord, R Perets, A Italiano, R Shapira-Frommer, ... Journal of Clinical Oncology 37 (17), 1470-1478, 2019 | 825 | 2019 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 751 | 2019 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 679 | 2018 |
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ... Clinical cancer research 18 (22), 6373-6383, 2012 | 575 | 2012 |
| Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial JS Frenel, C Le Tourneau, B O’Neil, PA Ott, SA Piha-Paul, C Gomez-Roca, ... Journal of Clinical Oncology 35 (36), 4035-4041, 2017 | 441 | 2017 |
| AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer D Hong, R Kurzrock, Y Kim, R Woessner, A Younes, J Nemunaitis, ... Science translational medicine 7 (314), 314ra185-314ra185, 2015 | 437 | 2015 |
| PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors F Janku, AM Tsimberidou, I Garrido-Laguna, X Wang, R Luthra, DS Hong, ... Molecular cancer therapeutics 10 (3), 558-565, 2011 | 430 | 2011 |
| Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials F Meric-Bernstam, L Brusco, K Shaw, C Horombe, S Kopetz, MA Davies, ... Journal of clinical oncology 33 (25), 2753, 2015 | 418 | 2015 |
| Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE‐158 and KEYNOTE‐028 studies SA Piha‐Paul, DY Oh, M Ueno, D Malka, HC Chung, A Nagrial, RK Kelley, ... International journal of cancer 147 (8), 2190-2198, 2020 | 348 | 2020 |
| Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ... Annals of Oncology 29 (8), 1807-1813, 2018 | 328 | 2018 |
| PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials F Janku, JJ Wheler, A Naing, GS Falchook, DS Hong, VM Stepanek, S Fu, ... Cancer research 73 (1), 276-284, 2013 | 311 | 2013 |
| Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies HC Chung, SA Piha-Paul, J Lopez-Martin, JHM Schellens, S Kao, ... Journal of Thoracic Oncology 15 (4), 618-627, 2020 | 308 | 2020 |
| Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ... Clinical Cancer Research 24 (12), 2804-2811, 2018 | 308 | 2018 |
| Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma T Doi, SA Piha-Paul, SI Jalal, S Saraf, J Lunceford, M Koshiji, J Bennouna Journal of Clinical Oncology 36 (1), 61-67, 2018 | 295 | 2018 |
| Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer F Meric-Bernstam, AM Johnson, EEI Dumbrava, K Raghav, K Balaji, ... Clinical Cancer Research 25 (7), 2033-2041, 2019 | 275 | 2019 |
| Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors F Janku, DS Hong, S Fu, SA Piha-Paul, A Naing, GS Falchook, ... Cell reports 6 (2), 377-387, 2014 | 272 | 2014 |
| Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal PA Ott, SA Piha-Paul, P Munster, MJ Pishvaian, EMJ Van Brummelen, ... Annals of Oncology 28 (5), 1036-1041, 2017 | 258 | 2017 |
